65. 原発性免疫不全症候群 Primary immunodeficiency Clinical trials / Disease details


臨床試験数 : 482 薬物数 : 653 - (DrugBank : 119) / 標的遺伝子数 : 90 - 標的パスウェイ数 : 211

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-jRCT2031200236
28/09/201710/12/2020Double-blind placebo-controlled clinical trial of thalidomide for chronic granulomatous disease-associated colitisDouble-blind placebo-controlled clinical trial of thalidomide for chronic granulomatous disease-associated colitis chronic granulomatous disease-associated colitis
primary immunodeficiency diseases; inflammatory bowel disease;D006105
1) Oral administration of thalidomide (1.5-3mg/kg), once a day
2) Oral administration of placebo (1.5-3mg/kg), once a day
Kawai ToshinaoKawai Toshinao;Japan Agency for Medical Research and DevelopmentRecruiting>= 1age oldNot applicableBoth8Phase 2-3Japan
2JPRN-UMIN000029324
2017/09/2801/10/2017Double-blind placebo-controlled clinical trial of thalidomide for chronic granulomatous disease-associated colitisDouble-blind placebo-controlled clinical trial of thalidomide for chronic granulomatous disease-associated colitis - Clinical trial of thalidomide for CGD colitis Chronic granulomatous disease associated colitisOral administration of thalidomide (1.5-3mg/kg), once a day
Oral administration of placebo (1.5-3mg/kg), once a day
National Center for Child Heath and DevelopmentNULLRecruiting1years-oldNot applicableMale and Female8Not selectedJapan
3JPRN-UMIN000009370
2012/12/0721/11/2012Thalidomide therapy clinical trial for chronic granulomatous disease-associated intractable granulomatous lesion Chronic granulomatous diseaseOral administration of thalidomideNational Center for Child Heath and DevelopmentNULLComplete: follow-up complete3years-oldNot applicableMale and Female5Not selectedJapan